Cowen analyst Joshua Jennings raised the price target on Boston Scientific (NYSE: BSX) to $53.00 (from $47.00) while maintaining an Outperform rating.

The analyst commented, "BSX posted 2Q revenue and EPS of $3.08B and $0.40, beating Street estimates of $2.94B and $0.37. Organic sales growth was 9% compared to 2Q'19. Management raised its full-year revenue and EPS outlook and issued 3Q guidance that, on its lower end, overlaps the current consensus forecasts. We believe BSX remains on track to return to its pre-pandemic norms by year-end. Increasing PT to $53 from $47."